ArticleACS omega2026
Chitosan-Coated Quercetin Nanoemulsion Eye Drops for Sustained Ocular Delivery and Protection of Lens Degeneration from Oxidative Stress.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quercetin is one of potent antioxidant. Its clinical utility is limited because of its poor solubility and bioavailability. Since oxidative stress is a cause of cataract formation, this study thus developed quercetin-loaded nanoemulsion (QNE) eye drops and further improved their efficacy by preparing in a form of chitosan-coated QNE (CS-QNE). It was found that CS enlarged the droplet size of QNE to 184.33 ± 0.71 nm and shifted the ζ-potential from negative to positive values. CS-QNE had entrapment efficiency of 99.99% with a pH of 6.0 ± 0.0, and shear-thinning behavior. Drug release study demonstrated that the release of quercetin from CS-QNE complied with a zero-order release kinetic. Furthermore, CS-QNE could effectively protect the HLE and HCE-T cells from H
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.